Related references
Note: Only part of the references are listed.Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Roman M. Chabanon et al.
CLINICAL CANCER RESEARCH (2016)
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Francesco Facchinetti et al.
CLINICAL CANCER RESEARCH (2016)
Methylated circulating tumor DNA in blood: power in cancer prognosis and response
Kristina Warton et al.
ENDOCRINE-RELATED CANCER (2016)
Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01)
Vania Tacher et al.
EUROPEAN JOURNAL OF CANCER (2016)
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
Ludmila Danilova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients
Steffen Dietz et al.
PLOS ONE (2016)
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease
Timothy M. Butler et al.
PLOS ONE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
Muhammed Murtaza et al.
NATURE COMMUNICATIONS (2015)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Evaluation of Exome Sequencing to Estimate Tumor Burden in Plasma
Daniel Klevebring et al.
PLOS ONE (2014)
Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing
K. C. Allen Chan et al.
CLINICAL CHEMISTRY (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety
C. A. Gomez-Roca et al.
ANNALS OF ONCOLOGY (2012)
Cell-free nucleic acids as biomarkers in cancer patients
Heidi Schwarzenbach et al.
NATURE REVIEWS CANCER (2011)
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing
Andreas Gnirke et al.
NATURE BIOTECHNOLOGY (2009)
Share Paper
